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1. Introduction
Cancer of the skin is the most common form of malignancy in humans and is divided into two
categories – non-malignant skin cancer and cutaneous melanoma. Non-melanoma skin cancer
(basal cell and small cell carcinoma) make up a vast majority of skin cancers. According to data
from National Cancer Institute (NCI) in 2012, more than 2 million new cases of non-melanomas
will be identified with less than a 1000 deaths. Despite according for only 4% of all cases,
melanoma is the deadliest of skin cancers resulting in over 79% of skin cancer deaths [1]. In
the United States, melanoma is the fifth most common cancer in men and the sixth most
common in women. In 2011, 70,230 new melanoma cases were identified with 8,790 deaths.
The median age of diagnosis is between 45-55; although 25% of melanomas occur in individ‐
uals over 40 years.
2. Types of skin cancer
a. Basal Cell Carcinoma (BCC): This is the most common form of skin cancer and accounts
for more than 90% of all skin cancers in the United States. BCC causes damage by growing
and invading the surrounding tissue and usually does not metastasize to other parts of
the body. Intermittent sun exposure (especially early in life), age and light colored skin
are important factors in the development of BCC. Approximately a fifth of BCCs, develop
in regions that are not sun-exposed such as chest, arms, neck, back and scalp [2]. Weak‐
ening of the immune system on account of the disease or immune-suppressive drugs is
known to promote the risk of developing BCCs. Usually BCC begins as a small, dome-
shaped bump and is covered by small superficial blood vessels called telangiectases and
its texture is often shiny and translucent. Hereditary predisposition to BCC [3,4] occurs
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among individuals with albinism and Xeroderma Pigmentosum. These disorders can be
linked to either instability of the skin or diminished pigmentation.
b. Squamous Cell Carcinoma (SCC): This cancer begins in the squamous cells that form the
surface of the skin, lining of hollow organs of the respiratory and digestive tracts. The
earliest form of SCC is called as actinic keratosis (AK) [2] that appear as rough, red bumps
on the scalp, face, ears and back of the hands. The rate at which the bumps (keratosis)
invade deeper in the skin to become fully developed squamous cell carcinoma is estimated
to be 10-20% over a 10 year period. Actinic keratinosis that becomes thicker and more
tender could increase the possibility of getting transformed to an invasive squamous cell
carcinoma phenotype. The most important risk factor is sun exposure. Lesions appear
after years of sun damage in the forehead, cheeks as well as the backs of hands. Other
minor factors like exposure to hydrocarbons, arsenic, heat or X-rays could predispose to
SCCs. Unlike BCC, SCCs can metastasize to other parts but are easy to treat.
c. Melanoma: This is the cancer of the melanocytes, the “skin-color producing cells” of the
body. An estimated 132,000 new cases of melanoma occur worldwide every year [5,6,7]
with approximately 65,161 deaths according to estimates from the World Health Organ‐
ization (WHO). The high mortality rate of melanoma is remarkably high considering the
fact that melanoma is nearly always curable in its early stages; the high mortality rate can
be attributed to late diagnosis in which the cancer spreads to other parts of the body [5].
Melanoma incidence has increased more rapidly than that of any other cancer, yet our
ability to treat disseminated disease has been lagging [8,9,10]. The predicted 1 year
survival for Stage IV melanoma ranges between 41% to 59% [11]. At a very early point in
the progression of melanoma, the cancer gains metastatic potential.
3. Risk factors
There  are  multiple  risk  factors  that  contribute  to  escalating  incidence  of  melanomas  in
humans  (Table  1).  Ultraviolet  (UV)  radiation  especially  UVA  (315-400  nm)  and  UVB
(280-315 nm) from sunlight is an important contributing factor for melanoma progression.
A study by Glanz et al [5,12] revealed that 90% of all melanomas are attributed to exposure
to ultraviolet radiation.
The damaging effects of UV radiation (UVR) is on account of direct cellular damage and
alterations in immunologic functions. UVR causes DNA damage (by formation of pyrimidine
dimers), gene mutations, oxidative stress, immunosuppressive and inflammatory responses.
All these effects play an important role in photoaging of the skin and predispose to skin cancer
[13]. UVR creates mutations in p53, a key tumor suppressor gene that plays an important role
in DNA repair and apoptosis. Thus if p53 is mutated, the cells lose the DNA repair process
leading to the deregulation of apoptosis, expression of mutated keratinocytes and initiation of
skin cancer [13,14]. Darker skinned individuals have lower incidence of cutaneous melanoma
primarily as a result of increased epidermal melanin. Studies indicate that epidermal melanin
in African-American individuals filters twice as much UVB radiation than in Caucasians. This
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is on account of the larger, more melanized melanosomes located in the epidermis of dark skin
individuals that absorb and scatter more light energy than the smaller, less melanized
melanosomes of white skin. The incidence rate of skin cancer (both melanoma and non-
melanoma) has increased significantly in the last decade [15]; particularly among young
women. For most individuals, exposure to UVR from the sun is the main source of skin cancer.
Nonetheless, some individuals are exposed to high UV doses through artificial sources –
sunbeds and sunlamps used for tanning purposes. Indoor tanning is widespread in most
developed countries in Northern Europe, Australia and the United States [16]. Intense early
sunburns and blistering sunburns are closely associated with melanoma development [17,18,
19]. Statistics indicate that one severe childhood sunburn is associated with a two-fold increase
in melanoma risk [20]. Chronic UV exposure results in increased skin aging, wrinkles, uneven
skin pigmentation, loss of elasticity and a distribution in the skin barrier function [21]. Chronic
UVR exposure is an important risk factor in the development of actinic keratosis (precursor of
SCCs).
Ultraviolet (UV radiation)
UVA
UVB
Genetic syndromes
Xeroderma pigmentosum
Oculocutaneous albinism
Basal cell nevus syndrome
Ionizing radiation
X-rays
Other risk factors
Artificial UV radiation (tanning)
Smoking
Color of skin (having fair skin, especially with blue or hazel eyes)
History of precursor lesions
Chronically injured or non-healing wounds
Working outdoors
Increasing age
Table 1. Risk factors for skin cancer [1-8]
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Candidate Gene Protein Location onchromosome Stage of melanoma References
Gene losses
PTEN Pten 10q Primary & metastatic [135,136,137]
CDKN2A p16Ink4a/p14Arf 9p Primary & metastatic [135,136]
ITGB3BP Beta-3-endonexin 1p31 Uveal [138]
Gene amplification
BRAF Braf 7q21.3 Cutaneous [135]
CCND1 cyclinD1 11q13 Acral [136]
CDK4 cdk4 12q14 Acral & mucosal [136]
CDH2 N-cadherin 18q Uveal & metastatic [137,139]
c-MYC c-myc 8q23 Ocular, primary &metastatic [135,137,140,141]
MITF Mitf 3p14 Cutaneous, metastatic [142,143]
Table 2. Chromosomal aberrations involving important genes found in melanoma
4. Roadway to melanoma
Malignant melanomas arise from epidermal melanocytes or the melanocyte precursor cell
which are derived from the neural crest and migrate to the skin and hair follicles [22]. Mela‐
noma initiation and progression is accompanied by a series of histological changes. The five
distinct changes are: 1) nevus – benign lesion characterized by an increased number of nested
melanocytes; 2) dysplastic nevus – which is characterized by random, discontinuous and
atypical melanocytes; 3) radial-growth phase (RGP) melanoma where the cells acquire the
ability to proliferate intraepidermally; 4) vertical growth phase (VGP) melanoma – character‐
ized by melanoma cells acquiring the ability to penetrate through the basement membrane
(BM) into underlying dermis and subcutaneous tissue; and 5) metastatic melanoma – charac‐
terized by the spread of melanoma cells to other areas of the skin and other organs. The most
critical event in melanoma progression is the RGP-VGP transition which involves the escape
from keratinocyte mediated growth control. This is consistent with tumor thickness being a
strong predictor of metastatic disease and adverse clinical outcome [23].
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Gene Protein Function Commentary References
Up-
regulation
ATM
ATM kinase Cell cycle control, DNAdamage response Melanocytic infiltration [135,136,137]
CDH2 N-cadherin Cell-cell adhesion Melanoma invasiveness [144,145]
MMP-1, 2 Metallo proteinases-1, 2 Degradation of ECM Tumor progression [146]
SPP1 Osteopontin Inductor of MMP Risk of metastasis [144,147]
SPARC Osteonectin Angiogenesis Tumor progression [144]
WNT5A Wnt5a Cell signaling Melanoma invasiveness [125,148]
CKS2 Cdc28/cdk1 proteinkinase subunit 2 Cell cycle control Poor prognosis [147]
EIF2gamma EIF2γ DNA translation Tumor progression [149]
PCNA PCNA Cofactor DNApolymerase Genome destabilization [150]
Down Regulation
CDH1 E-cadherin Cell-cell adhesion Tumor progression [144,145,147]
CDH3 P-cadherin Cell-cell adhesion Tumor progression [145,151]
CDH10 Cadherin-10 Cell-cell adhesion High risk of metastasis [144]
DSC1 Desmocollin-1 Desmosomalcomponent Loss of cell adhesion [137,139,179]
Table 3. Genetic expression signatures associated with the progression of melanomas [24]
Acquisition of somatic mutations in key regulatory genes is the driving force behind the
initiation and progression of melanoma development. For the past few decades numerous
research teams around the world have researched on melanoma genetics leading to an
overwhelming body of information.
5. Susceptibility genes
Approximately 8-12% of all melanomas are familial – occurring in individuals with a history
of familial melanoma [24]. Two genes have been found to be associated with high pene‐
trance susceptibility – CDKN2A and CDK4. Using linkage analysis of families with high
melanoma  incidences,  the  first  melanoma  incidence  susceptibility  gene,  CDK2N2A  was
identified  at  chromosome 9p21  [25,26].  The  gene  CDKN2A encodes  two unrelated  pro‐
teins  –  p16Ink4A  and  p14Arf.  These  proteins  are  tumor  suppressors  involved  in  cell  cycle
regulation.  Numerous  studies  indicate  that  p16Ink4A  inhibits  G1  cyclin  dependent  kinase
(cdk4/cdkb)  mediated  phosphorylation  of  retinoblastoma  protein  (pRB)  resulting  in  cell
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cycle progression arrest  through G1-S;  while p14 favors apoptosis  and blocks oncogenic
transformation  by  stabilizing  p53  levels  through  the  inhibition  of  Mdm2-mediated  p53
ubiquitination [27,28,29,30]. Loss of p16 promotes hyper-phosphorylation of pRb resulting
in its inactivation while the loss of p14 inactivates p53 — leading to unrestricted cell cycle
progression. Germline mutations in CDKN2A have been found in 40% of families with 3
or more family members affected by melanoma [31].  Not all  individuals carrying germ‐
line CDKN2A mutations develop mutations.  Individuals with large numbers of pigment
lesions or nevi have familial atypical mole-melanoma syndrome (FAMS) are associated with
increased risk to developing melanoma [32,33].
The other melanoma susceptibility gene, CDK4 is located at chromosome 12q14 [34,35,36].
Mutations in CDK4 abrogate binding of cdk4 to p16 have been associated with melanoma
pathogenesis [32]. This is evidence that links the entire p16Ink4A-cdk4/cdk6-pRb pathway to
melanoma indicating that hereditary retinoblastoma patients with germline inactivation of
retinoblastoma (Rb1) are predisposed to melanoma [37,38].
6. Acquired genetic alterations in melanoma
Understanding the regulating pathways involved in melanoma development and progression
has advanced significantly in recent years. The discovery of genetic alterations that aids in the
formation of various cancers has aided in the development of numerous molecularly targeted
therapies for individuals with metastatic disease [39,40,41]. These genes are known to be key
molecular driver in melanoma; >70% cases harbor activating mutations in these genes. The
molecule that is most commonly found to be mutated in melanomas is BRAF (~50% of all
cancers) followed by NRAS (20%) and c-kit (1%) [42,43,44]. Melanoma is the result of complex
changes in multiple signaling pathways affecting growth, cell mobility, metabolism and the
ability to escape cell death progression. The Ras-Raf-Mek-Erk pathway followed by PI3K/Akt
pathway is constitutively activated in a significant number of melanoma tumors.
7. The Ras-Raf-Mek-Erk
In  2002,  a  breakthrough  study  found that  Braf  to  be  mutated  in  a  large  percentage  of
melanomas – triggering new studies that focus on MAPK (mitogen activated protein kinase)
signaling in melanomas.  Braf  is  mutated in upto 82% of  cutaneous nevi  [45,46],  66% of
primary  melanomas  [44]  and 40-68% of  metastatic  melanomas  [47,48].  A  specific  muta‐
tion substitution of valine with glutamic acid at residue 600 (BRAF V600E), account for 90%
+ BRAF mutation. Raf, a downstream effector of RAS is a serine-threonine specific protein
kinase that activates Mek, which inturn activates Erk. Humans have 3 Raf genes: A-raf, B-
raf  and C-raf.  The  occurrence  of  mutation  in  Nras  or  Braf  is  80-90% of  all  melanomas
suggests that constitutive activation of extracellular signal regulated protein kinase (Ras-
Raf-Mek-Erk). Most Ras mutations are present in codon 61 of N-Ras with K-Ras and H-
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Ras  mutations  being  relatively  rare  [49,50].  Constitutive  activation  of  Ras-Raf-Mek-Erk
cascade  has  been  shown  to  contribute  to  tumorigenesis  by  inhibiting  apoptosis  and
increasing cell proliferation, tumor invasion and metastasis. Activated Erk plays a pivotal
role in cell  proliferation by controlling the G1- to S-phase transition by negative regula‐
tion of p27 inhibition and upregulation of c-myc activity [51,52]. Inhibition of Erk activity
is associated with G1 cell cycle arrest by upregulation of p21 and reduced phosphoryla‐
tion  [52].  Activated  Erk  is  also  known  to  stimulate  cell  proliferation  by  increasing  the
transcription and stability of c-Jun which is mediated by CREB (cyclic adenosine monophos‐
phate responsive element-binding) and Gsk-3β (glycogen synthase kinase-3beta) respective‐
ly  [53].  Erk  is  also  believed  to  increase  proliferation  by  inhibiting  differentiation.
Constitutively  active  Erk  limits  differentiation  in  melanoma  by  targeting  MITF  (micro‐
phthalmia-associated  transcription  factor)  for  degradation  [54,55,56].  The  activated  Erk
pathway enhances melanoma specific survival by differentially regulating RSK-mediated
phosphorylation and inactivation of the pro-apoptotic protein Bad [57] and inhibiting Jak-
Stat pathway [58].
Erk signaling also contributes towards tumor invasion and metastasis by regulating the
expression of integrin and matrix metalloproteinases (MMPs). Activated Ras-Mek-Erk
pathway drives the production of MMP1 [59,60,61].
8. The PI3K/Akt pathway
The PI3K/Akt pathway is activated in various cancers, mostly on accont of mutations in tumor
suppressor PTEN (phosphatase and tensin homolog) [62]. In melanoma, los of PTEN on
chromosome 10q 23-24 was first reported by Parmiter et al [63]. The PTEN gene encodes a
phosphatase that degrades products of PI3K by dephosphorylating phosphatidylinositol 3,4,5-
triphosphate and phosphatidylinositol 3,4-biphosphate at 3 positions [64]. Loss of PTEN
increases AKT phosphorylation and activity leading to increased mitogenic signaling and
decreased apoptosis [65]. Various studies suggest that 30-40% of melanoma cell lines and 5-15%
of uncultured melanoma specimens carry inactivating mutations or homozygous deletions of
Pten [63,66,67].
Pten encodes a negative regulator of extracellular growth signals that are transcended via
PI3K-Akt pathway. Akt/protein kinase B (PKB), a serine-threonine kinase, is a core component
of the PI3K signaling cascade and is activated through the phosphorylation of Ser 473/474 and
Thr 308/309 [68,69]. Activated Akt regulates a network of factors that control cell proliferation
and survival and this pathway is hyperactive in most metastatic melanomas [70,71,72]. Akt
activates the transcription of a wide variety of genes involved in a wide range of cellular
activities – those involved in immune activation, cell proliferation, apoptosis and cell survival
[69]. Several studies have documented Akt activation in melanoma. Dai et al undertook a 292
sample study of pAkt levels using tissue microarray & immunohistochemistry strategies and
identified strong pAkt expression in 17%, 43%, 49% and 77% of the biopsies in normal nevi,
dysplastic nevi, primary melanoma and melanoma metastasis respectively. An important cell
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adhesion protein MelCAM that plays critical roles in melanoma development was increased
upon active Akt expression [73,74]. PI3K and Akt is known to increase the expression of MMP2
and MMP9 by a mechanism involving Akt activation of NF-kappaB binding to the MMP
promoter [75,76]. Akt overexpression led to upregulation of VEGF, increased production of
superoxide ROS. Akt can suppress apoptosis by phosphorylating and inactivating many
proapoptotic proteins like caspase 9 and Bad [77,78]. PI3K pathway emerges as the central axis
that is deregulated in melanoma and along with constitutively active MAPK pathway makes
an important role in melanoma development progression. Thus targeting PI3K is expected to
be an important therapeutic target modality for melanoma treatment.
9. Wnt/β-catenin pathway
Βeta-catenin (β-catenin) is a key component of the Wnt signaling pathway. Signaling through
this pathway controls a wide range of cellular functions and aberrant Wnt/β-catenin signaling
can lead to cancer development and progression [79]. Wnts are glycoproteins that act as ligands
to stimulate receptor-mediated signal transduction pathways involved in cell survival,
proliferation, behavior and fate. Wnt proteins are known to activate 3 different extracellular
pathways – Wnt/β-catenin, Wnt/planar-polarity and Wnt/Ca2+ pathways [80]. The Wnt/β-
catenin also known as the canonical Wnt pathway plays an important role in melanoma
development. In the absence of Wnt ligands, free β-catenin binds to the destructive complex
of Axin, adenomatous polyposis coli (APC) and glycogen synthase kinase-3β (GSK-3β).
GSK-3β mediates the phosphorylation of β-catenin at specific regulatory sites on the N-
terminal side marking β-catenin for ubiquitination and subsequent proteosomal degradation.
Upon the binding of Wnt ligand, GSK--catenin for ubiquitination and subsequent proteosomal
degradation. Upon the binding of Wnt ligand, GSK-3β activity is inhibited resulting in
accumulation of β-catenin in the cytoplasm and shuttles into the nucleus where it serves as an
essential co-activator of the Tcf/Lef (T-cell factor / lymphoid enhancer factor) family [81].
Numerous genes implicated in the tumorigenic process like c-myc and cyclinD1 have been
identified as targets of the canonical Wnt signaling.
Increased nuclear localization of β-catenin – an important indication of activated Wnt signaling
pathway is observed in over a third of melanoma specimens [82,83,84]. Mutations in β-catenin
have been observed in about 23% of melanoma cancer cell lines and these mutations affect
phosphorylation sites at Ser33, Ser37, Thr41 and Ser45 [85] at the N-terminal domain. These
mutations render β-catenin resistant to phosphorylation and subsequent degradation. Low
rates of β-catenin mutation have been observed in primary melanomas and metastasis
indicating that activating mutations is a rare event in melanoma tumorigenesis
[82,83,84,86,87,88]. Mutations in APC were observed sporadically in primary melanomas [82,
85,88]. While APC promoter 1A hypermethylation was observed in 17% of melanoma biopsies
and 13% of melanoma cell lines. Wnt signaling pathways is activated in tumors through
aberration in other genes. ICAT (inhibition of β-catenin & T-cell factor), a gene that negatively
regulates the association of β-catenin with TCF4 thus repressing the transactivation of β-
catenin-Tcf4 target genes [89]. A study by Reifenberger J et al suggests that loss of ICAT
Highlights in Skin Cancer50
expression may contribute to the progression of melanoma [86]. ICAT mRNA expression
analysis in two-third melanoma specimens revealed a 20% or less decrease in ICAT transcrip‐
tion [86]. However the mechanism behind the reduced ICAT mRNA level in melanoma is
unclear.
Identification of Wnt target genes is also important towards the study of melanoma progres‐
sion. Brn1, the POU domain transcription factor is directly controlled by Wnt signaling in
transgenic mouse models and melanoma cell lines [90]. Studies indicate that overexpression
of Brn2 is associated with increased melanoma progression and tumorigenicity [90,91].MITF
(microphthalmia-associated transcription factor), a Wnt target gene, is essential for the
development of the melanocyte lineage and has an important role in the control of cell
proliferation, survival and differentiation [54,92,93]. The regulation of MITF expression by β-
catenin significantly influences the growth and survival behavior of treatment resistant
melanoma [94]. A study by Schepsky A et al demonstrated that MITF can directly interact with
β-catenin and redirect transcriptional activity away from canonical Wnt signaling-regulated
target gene specific for MITF [95]. Induction of Wnt signaling can be blocked by 5 different
proteins – Dkk, Wise, sFrp (secreted Frizzled related protein), Wif (wnt inhibitory factor), and
Cerebrus that compete for the Wnt ligand or the Lrz-Frp receptor [96]. Interestingly, Dkk1
(Dickkopf 1) expression is negligible in melanomas [97]. Studies by Kuphal et al have dem‐
onstrated a downregulated or loss of Dkk-1, -2 and-3 in all melanoma cell lines and most of
the melanoma tumor samples that were analyzed [98]. In xenograft mouse model, overex‐
pression of Dkk-1 and Wif-1inhibited melanoma tissue growth [99,100].
10. The JNK/c-Jun pathway
Activation of Jnks is usually in response to diverse stresses. These kinases play an important
role in the regulation of cell proliferation, cell survival, cell death, DNA repair and metabolism.
A variety of extracellular stimuli by cytokines, growth factors, hormones, UV radiation and
tumor promoters are known to activate Jnks [101]. Sequential protein phorphorylation through
a MAP-kinase module (MAP3K-MAP2K-MAPK) is responsible for Jnk activation [102].
Depending upon the cellular context, Jnk has been shown to elicit both positive and negative
effects on tumor development [103]. Activation of Jnk is required for Ras-mediated transfor‐
mation and mediate proliferation and tumor growth [104,105]. These observations are
consistent with the findings of constitutively active Jnk in tumor samples and cell lines
[103,106]. Jnk mediated the phosphorylation at serine 63 & 73 residues enhancing the ability
of transcription factor c-Jun, a component of the AP-1 transcription complex [107]. The
activation of Jnk leas to the induction of AP-1 dependent target genes that play important roles
in cell proliferation, cell death and inflammation. Other members of the AP-1 transcription
complex include c-Jun, Jun B, Jun D, c-Fos, Fra1 and Fra 2. The role of Jnk in oncogenesis is
emerging; however c-Jun is a well defined oncogene in cancer. c-Jun is amplified and overex‐
pressed in undifferentiated and aggressive sarcomas [108], breast and lung cancer [109,110].
Since the 1990s, the role of Jnk pathway in melanomas was recognized [111,112]. c-Jun, Jun B,
c-fos genes play a role in the transformation of melanocytes into malignant melanomas [111].
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The possible role Jnk pathway has led research teams to study the clinical relevance of
interfering with this pathway. siRNA or chemical inhibitors of Jnk signaling inhibited
proliferation in breast and non-small cell lung cancer (NSCLC) [106,113] and also induced
apoptosis in prostate cancer cells [114]. A study by Gurzov E et al demonstrated that knock‐
down of c-Jun and Jun B in B16F10 melanoma cells by siRNA resulted in increased cell cycle
arrest and apoptosis also resulting in extended survival of mice inoculated with these modified
melanoma cells[115], suggesting that inactivation of c-Jun and Jun B could provide a valuable
strategy for antitumor intervention [115].
11. The NFκB (NF-kappaB) pathway
The NFκB family in mammals contains 5 members – p105/p50 (NFκB1), p100/p52 (NFκB2),
RelA (p65), RelB and c-Rel (J-206, 207). The canonical activation of NFκB pathway involves
TNFα stimulation resulting in the subsequent phosphorylation/activation of IKK (IκB kinase).
In turn, IKK-mediated phosphorylation of IκB leading to ubiquitination of IκB and its
proteosomal degradation, releasing the NFκB complex which activates a host of target genes
[116,117]. The type of genes that get trans-activated depends on the composition of activated
NFκB complex. For instance, complexes containing c-Rel activates pro-apoptotic genes (Dr4/
Dr5, Bcl-x) and inhibits anti-apoptotic genes (cellular inhibitor of apoptosis (cIAP1, cIAP2),
survivin). Complexes containing RelA inhibits the expression of DR4/DR5 and upregulates
caspase 8, cIAP1 and cIAP2 [118].
NFκB is activated in various tumors including melanomas and distinct mechanisms have been
proposed for the elevated levels of NFκB activity in melanomas. Activation of NFκB in
melanomas is also linked to the loss of E-cadherin, a frequent event in melanoma transforma‐
tion [119]. NIK (NFκB interacting kinase), an activator of IKK is overexpressed in melanoma
cells while compared to normal cells. The major contribution of NFκB in melanoma develop‐
ment and progression relates to its function as an important regulator of survival and apop‐
tosis. A study by Meyskens at al demonstrated that in metastatic melanoma cells, an increase
in DNA binding activity of NFκB is associated with an increased expression of p50 and RelA
resulting in increased expression of anti-apoptotic regulators. Also the expression of c-Rel, the
transcriptional activator of pro-apoptotic genes is markedly in melanoma cells compared with
normal melanocytes [120]. Strong p50 nuclear staining also correlated with poor prognosis in
melanoma patients [121]. Besides eliciting anti-apoptotic activities NFκB mediates the
transcription of MMP2 and MMP9 [121,122]. Overexpression of MMPs is associated with
tumor invasion, metastasis and angiogenesis.
12. Melanoma stem cells
Stem cells are cells that can self-renew and the ability to differentiate into various cell lineages.
These cells are located in the restrictive niche (environment). The interaction between stem
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cells and their microenvironment is important for the self renewal process. These cells are
highly clonogenic and slow cycling (quiescent) in response to proliferation and survival
stimuli. Stem cells divide asymmetrically giving rise to a daughter cell that remains a stem cell
(capable of self renewal) and another daughter cell that can rapidly divide and differentiate.
Melanocytes that are found in the skin and in the choroid layer of the eye is derived from the
neural crest (NC). Neural crest cells undergo EMT to migrate along the definite pathways in
the embryo. NC cells give rise to a large array of differentiated cells – melanocytes, peripheral
neurons & glia, endocrine and cartilage cells [123]. Melanoblasts which are melanocytic
precursors – unpigmented cells with the potential to produce melanin, invade the skin areas
and differentiate into melanocytes.
The cancer stem theory suggests that cancer originates from a small subpopulation of neo‐
plastic stem cells that have the potential to self renew and are primarily responsible for
sustaining the tumor and giving rise to progressively differentiating cells that proliferate
rapidly and contribute to the cellular heterogeneity of the tumor (F-194). Cancer stem cells
arise either from undifferentiated stem cells or from cells that possess stem cell like character‐
istics. Evidence suggests that aggressive melanoma cells acquire characteristics of embryonic
stem cells having a multipotent plastic phenotype [124]. Studies by Bittner MP et al demon‐
strated that melanoma cells express genes associated with different cell types like endothelial,
epithelial, fibroblastic, neuronal, hematopoietic and progenitor cells [125]. Strangely genes
specific for melanocytes are downregulated in metastatic melanomas. Tyrosinase & MLANA
(melan A), genes associated with pigmentation are greatly downregulated in aggressive
melanomas [124]. Aggressive melanoma cells express endothelial-associated genes and form
extravascular fluid-conducting networks which allow melanomas to greatly adapt to the
hypoxic microenvironment of rapidly proliferating tumors, a phenomenon called as “vascular
mimicry” [124,126]. From different melanoma cell lines, cells with stem cell-like features which
have the ability to grow as non-adherent cell aggregates known as spheroids/spheres have
been isolated (F-196). These cells have the ability to differentiate into various lineages –
adipogenic, osteogenic, chondrogenic and melanogenic. A study by Bittner M et al demon‐
strated a subset of these spheroid cells express the cell surface marker CD20, a unique
molecular signature of aggressive melanomas [125]. For the treatment of non-Hodkin’s
lymphoma, CD20 is a standard therapeutic target which raises the possibility that CD20 could
be used as a potential target for melanoma treatment [127].
Several studies have demonstrated that aggressive melanoma cells share characteristics with
embryonic progenitors. Evidence suggests a major role for stromal components in all stages
of tumorigenesis (initiation, progression and metastasis) [128]. Noted scientist Stephen Paget
had coined the term “seed & soil” hypothesis predicting that metastatic cells only colonize
soils (organs) that are permissive to their growth[129,130]. Studies show embryonic microen‐
vironment has the capacity to reverse the metastatic phenotype of cancer cells. The microen‐
vironment of human embryonic stem cells reprograms aggressive melanoma cells towards a
less aggressive phenotype [124]. Nodal, an embryonic morphogen of the TGFβ family is
important for sustaining melanoma aggressiveness and plasticity. Nodal is regained in highly
aggressive melanoma cell lines, invasive VGP (vertical growth phase)-stage melanoma and
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metastatic melanoma [131], implicating Nodal as a novel diagnostic marker in melanoma
progression and could be a therapeutic target for metastatic melanoma treatment [124].
13. Conclusion
Our understanding of melanoma development and progression has evolved tremendously
over the past three decades. Unfortunately our understanding of the molecular biology of
melanoma is still far from complete despite extensive research and knowledge gained in
chromosomal alterations, mutations in important melanoma-associated genes, epigenetic
modifications and melanoma microenvironment. Even to this day, the best prognostic
significance of primary melanoma is the thickness of the tumor (i.e. RGP → VGP transition)
and the presence/absence of ulcerations. Melanoma still remains as a tumor that is refractory
to current chemotherapeutic treatments. A further study of the interaction between various
signaling pathways will help researchers decipher the complexity of the genetic and epigenetic
changes which eventually would lead to better therapeutic modalities for the treatment of
primary and metastatic melanomas.
Glossary
AK - actinic keratosis
BCC - basal cell carcinoma
Cdks - cyclin-dependent kinases
CREB - cyclic adenosine monophosphate responsive element-binding
FAMS - familial atypical mole-melanoma syndrome
GSK3β - glycogen synthase kinase-3beta
IKK - Inhibitor of IκB kinase
MAPK - mitogen activated protein kinase
MITF - microphthalmia-associated transcription factor
MMP - matrix metalloproteinase
NF-κB - nuclear factor kappa-B
NIK - NFκB-interacting kinase
Pten - phosphatase and tensin homolog
Rb - retinoblastoma
RGP - radial growth phase
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SCC - Squamous cell carcinoma
Tcf4 - T-cell factor-4
UVR - ultraviolet radiation
VGP - vertical growth phase
WIF1 - Wnt-inhibitory factor 1
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